Zimmer Biomet Completes Acquisition of Monogram Technologies, Expands Robotics Portfolio
PorAinvest
martes, 7 de octubre de 2025, 4:39 pm ET1 min de lectura
MGRM--
Under the terms of the merger agreement, each outstanding share of Monogram common stock will be converted into $4.04 in cash plus non-tradeable contingent value rights worth up to $12.37 if development, regulatory, and revenue milestones are met by 2030. Monogram shares will be delisted from Nasdaq following the transaction [2].
The acquisition enhances Zimmer Biomet's capabilities in orthopedic robotics, particularly in semi-autonomous and fully autonomous surgical systems. Monogram's surgeon-guided, CT-based systems will complement Zimmer Biomet's existing Rosa Robotics platform and other navigation tools, offering surgeons a broader range of robotic and navigation options.
Zimmer Biomet's CEO, Ivan Tornos, commented, "By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings. We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings" [2].
The acquisition is expected to be neutral to adjusted earnings per share in 2025-2027 and accretive thereafter, contributing to revenue growth beginning in 2027. The transaction is funded through a combination of cash on the balance sheet and other available debt financing sources [1].
ZBH--
Zimmer Biomet Holdings, a global medical technology leader, has completed the acquisition of Monogram Technologies Inc., an AI-driven orthopedic robotics company. The transaction creates a broad portfolio of orthopedic robotics and navigation technologies, including a pathway towards fully autonomous robotic technology for orthopedic procedures. Zimmer Biomet's acquisition of Monogram is expected to add new capabilities to its existing suite of technology solutions, making it a leader in the field of orthopedic robotics and navigation.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has completed the acquisition of Monogram Technologies Inc. (NasdaqCM: MGRM), an AI-driven orthopedic robotics company, for approximately $150 million [1]. The acquisition, announced in July 2025, aims to expand Zimmer Biomet's portfolio of orthopedic robotics and navigation technologies, positioning the company as a leader in the field.Under the terms of the merger agreement, each outstanding share of Monogram common stock will be converted into $4.04 in cash plus non-tradeable contingent value rights worth up to $12.37 if development, regulatory, and revenue milestones are met by 2030. Monogram shares will be delisted from Nasdaq following the transaction [2].
The acquisition enhances Zimmer Biomet's capabilities in orthopedic robotics, particularly in semi-autonomous and fully autonomous surgical systems. Monogram's surgeon-guided, CT-based systems will complement Zimmer Biomet's existing Rosa Robotics platform and other navigation tools, offering surgeons a broader range of robotic and navigation options.
Zimmer Biomet's CEO, Ivan Tornos, commented, "By bringing Monogram into the Zimmer Biomet innovation ecosystem, we have set a bold course to become the first orthopedic company to offer a fully autonomous robotic solution complementing our current robotic and navigation offerings. We aim to provide surgeons the broadest choice in robotics and navigation across a wide range of procedures and care settings" [2].
The acquisition is expected to be neutral to adjusted earnings per share in 2025-2027 and accretive thereafter, contributing to revenue growth beginning in 2027. The transaction is funded through a combination of cash on the balance sheet and other available debt financing sources [1].
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios